Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s share price was up 0.2% during trading on Friday . The stock traded as high as $10.52 and last traded at $10.52. Approximately 814 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 17,307 shares. The stock had previously closed at $10.50.
Drugs Made in America Acquisition Trading Up 0.2%
The firm has a fifty day moving average price of $10.49 and a two-hundred day moving average price of $10.49.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Featured Stories
- Five stocks we like better than Drugs Made in America Acquisition
- Wall Street Stockpicker Names #1 Stock of 2026
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Claim Your Share of $5.39 BILLION in AI Equity Checks
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
